দেশ: মাল্টা
ভাষা: ইংরেজি
সূত্র: Malta Medicines Authority
Przedsiebiorstwo Farmaceutyczne LEK-AM sp. z o.o 14A Ostrzykowizna Street, 05-170 Zakroczym, , Poland
N05CH01
MELATONIN 2 mg
PROLONGED-RELEASE TABLET
MELATONIN 2 mg
POM
PSYCHOLEPTICS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2023-03-02
Page 1 of 7 B. PACKAGE LEAFLET Page 2 of 7 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT MELDREAM PR 2 MG PROLONGED-RELEASE TABLETS Melatonin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See Section 4. WHAT IS IN THIS LEAFLET: 1. What Meldream PR is and what it is used for 2. What you need to know before you take Meldream PR 3. How to take Meldream PR 4. Possible side effects 5. How to store Meldream PR 6. Contents of the pack and other information 1. WHAT MELDREAM PR IS AND WHAT IT IS USED FOR The active substance of Meldream PR, melatonin, belongs to a natural group of hormones produced by the body. Meldream PR is used on its own for the short-term treatment of primary insomnia (persistent difficulty in getting to sleep or staying asleep, or poor quality of sleep) in patients aged 55 years and older. ‘Primary’ means that the insomnia does not have any identified cause, including any medical, mental or environmental cause. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MELDREAM PR DO NOT TAKE MELDREAM PR - if you are allergic to melatonin or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Meldream PR: - If you suffer from liver or kidney problems. No studies on the use of Meldream PR in people with liver or kidney diseases have been performed, you should speak to your doctor before taking Meldream PR as its use is not recommended. Page 3 of 7 - If you have been told by your doctor that you have an intolerance to some sugars. - If you have been told সম্পূর্ণ নথি পড়ুন
Strona 1 z 12 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Strona 2 z 12 1. NAME OF THE MEDICINAL PRODUCT Meldream PR, 2 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 2 mg melatonin. Excipient with known effect: each prolonged-release tablet contains 80 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. White to off-white, round (8.0 ± 0.3 mm diameter), biconvex tablets 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Meldream PR is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 2 mg once daily, 1-2 hours before bedtime and after food. This dosage may be continued for up to thirteen weeks. _Paediatric population _ The safety and efficacy of Meldream PR in children aged 0 to 18 years has not yet been established. Other pharmaceutical forms/strengths may be more appropriate for administration to this population. Currently available data are described in section 5.1. _Renal impairment _ The effect of any stage of renal impairment on melatonin pharmacokinetics has not been studied. Caution should be used when melatonin is administered to such patients. _Hepatic impairment _ Strona 3 z 12 There is no experience of the use of Meldream PR in patients with liver impairment. Published data demonstrates markedly elevated endogenous melatonin levels during daytime hours due to decreased clearance in patients with hepatic impairment. Therefore, Meldream PR is not recommended for use in patients with hepatic impairment. Method of Administration Oral use. Tablets should be swallowed whole to maintain prolonged release properties. Crushing or chewing should not be used to facilitate swallowing. 4.3. CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4. S সম্পূর্ণ নথি পড়ুন